You are here: Industry Insights > Sarepta

News List

Sarepta taps Invitae to identify participants for DMD trials fiercebiotech
May 08, 2018
Sarepta Therapeutics has partnered with genetic testing company Invitae to identify participants for its Duchenne muscular dystrophy (DMD) clinical trials. The initiative taps into the networks Invitae ...
Sarepta adds muscular dystrophy gene therapies via Myonexus pact fiercebiotech
May 07, 2018
Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company.
CHMP takes negative view on Sarepta’s DMD therapy pharmatimes
May 07, 2018
Sarepta has indicated that there could be a delay to getting its Duchenne muscular dystrophy therapy Exondys approved in Europe, revealing that the European Medicine Agency’s Committee for Medicinal Products for Human Use’s trend vote was negative.
Sarepta Shows Off Long-Term Pulmonary Function of Eteplirsen-Treated DMD Patients biospace
December 28, 2017
Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
Sarepta sells FDA priority review voucher to Gilead for $125 million firstwordpharma
February 22, 2017
Sarepta Therapeutics disclosed Tuesday that it entered an agreement to sell its rare paediatric disease priority review voucher to Gilead Sciences for $125 million.

Previous page 1 2 Next page